Neurofibromatosis is a neurocutaneous disorder characterized by tumors in the nervous system and skin. Neurofibromatosis types 1 and 2 are the most common and are distinct entities. Neurofibromatosis type 1 or von Recklinghausen's disease is an autosomal dominant disease. Neurofibromatosis type 1 presents with neurofibromas, cafe-au-lait macules, freckling, and optic gliomas. It is a clinical diagnosis. Neurofibromatosis type 2 (NF2) is a disease characterized by bilateral vestibular schwannomas (VS) and meningiomas. It has an autosomal dominant inheritance pattern. Treatment for neurofibromatosis types 1 and 2 is clinical monitoring and medical intervention when appropriate.
Neurofibromatosis type 1 is caused by a loss of function mutation, either de novo or inherited, on the neurofibromin 1 (NF1) gene. It is located on band 17q11.2 and codes for neurofibromin. Neurofibromin is a tumor suppressor that functions in the RAS/MAPK and mTOR pathways. Mosaicism can occur resulting in segmental, generalized, or gonadal NF1 gene. Segmental NF1 gene has pigment changes, tumors, or both that are limited to one or more body segments. Generalized NF1 gene appears similar to classic NF1 but does not have the NF1 gene mutation. Gonadal NF1 gene occurs when the mutation only affects the ova or sperm.
NF2 gene is caused by a loss of function mutation of the NF2 gene. It is located on band 22q12 and codes for merlin. Merlin is a cell membrane protein that is also a tumor suppressor that functions in the PI3kinase/Akt, Raf/MEK/ERK, and mTOR pathways. 
Neurofibromatosis type 1 makes up about 96% of all neurofibromatosis cases. Prevalence is 1 in 3000 births. It occurs equally between gender and races. Fifty percent of patients have a spontaneous mutation, and the other half have an inherited mutation. There is a 100% penetrance with variable expressivity. Neurofibromatosis type 2 makes up about 3% of all cases and has a prevalence between 1 in 33,000 births and 1 in 87,410. There is no gender or race predilection. Neurofibromatosis type 2 has variable presentations amongst different families. A more severe clinical presentation is associated with a frameshift or a nonsense mutation that result in a truncated protein. 
Neurofibromas are benign tumors with mixed cell types including Schwann cells, perineural cells, and fibroblasts. The tumors also contain mast cells, axonal processes, and a collagenous extracellular matrix.
Plexiform neurofibromas are similar to neurofibromas, but they arise from muscle nerve fascicles and can infiltrate into the surrounding structures.
Neurofibromatosis type 1 has cutaneous and noncutaneous manifestations. Cafe-au-lait macules are one of the seven diagnostic criteria for neurofibromatosis type 2. The lesions are sharply demarcated with a homogenous appearance. Axillary and groin freckling, or Crowe sign, is the most specific criteria for neurofibromatosis type 2. Neurofibromas can occur anywhere on the body. They can be cutaneous or internal. Dermal tumors are soft dome-shaped tumors but can also present as pedunculated, nodular, or plaque-like. Internal tumors are deeper and can occur around the eye, retroperitoneal, along with the gastrointestinal (GI) tract, or in the mediastinum. Neurofibromas have the buttonhole sign. Plexiform neurofibromas are usually present from birth and are derived from the nerve sheaths. They can feel like a "bag of worms." Cutaneous manifestation includes scoliosis, long bone dysplasia, learning difficulties, and attention deficit hyperactivity disorder (ADHD). Lisch nodules are hyperpigmentation in the iris. They do not affect vision. Optic glioma is a tumor of the optic nerve and can affect vision. It occurs in 15% of neurofibromatosis type 1 patients. Patients also have generalized hyperpigmentation, blue-red, pseudoatrophic macules, juvenile xanthogranuloma, glomus tumor, melanoma, nevus anemicus, and pruritus. Patients are at increased risk for rhabdomyosarcoma, myeloid leukemia, and pheochromocytomas.
Neurofibromatosis type 2 patients present most commonly with schwannomas and meningiomas. Bilateral vestibular schwannoma and unilateral vestibular schwannoma occur on the superior division of the eighth cranial nerve. This is the most common type, but it can occur with any cranial nerve. Involvement of the facial nerve with the vestibular schwannoma can make surgical treatment difficult. These patients present with tinnitus, hearing loss and difficulty with balance. Patients that have the truncated protein were found to have the disease of onset at a younger age and a higher prevalence of tumors. Younger patients also have an earlier onset of symptoms.
NIH has seven diagnostic criteria for neurofibromatosis type 1. Two must be met for the diagnosis of neurofibromatosis type 1. Genetic testing is not routinely done.
Differential diagnosis includes neurofibromatosis type 1-like syndrome, familial cafe-au-lait spots, and segmental neurofibromatosis type 1. The nf1-like syndrome was first described in 2007. Patients with the neurofibromatosis type 1-like syndrome have cafe-au-lait spots, axillary freckling, and macrocephaly but they lack the NF1 genetic mutation, neurofibromas, and Lisch nodules. It is an autosomal dominant disease due to a mutation in SPRED1 gene on chromosome 15. Familial cafe-au-lait spots is a disorder presenting with only cafe-au-lait macules.
Bilateral vestibular schwannoma is pathognomic for neurofibromatosis type 2, but not all patients with neurofibromatosis type 2 have bilateral vestibular schwannoma. The NIH has diagnostic criteria for neurofibromatosis type 2.
Definitive Neurofibromatosis Type 2
Presumptive or Probable Neurofibromatosis Type 2
Cafe-au-lait spots and neurofibromas are benign and do not require treatment. Surgical excision can be performed on symptomatic lesions, but recurrence can occur. Plexiform neurofibromas have malignant potential. There is an 8% to 13% risk for plexiform neurofibromas to develop into malignant peripheral nerve sheath tumors. This should be suspected if there is a pain for more than one month, new neurologic deficits, change of the neurofibroma from soft to hard, or rapid increase in size. These malignancies are treated with wide local excision. Imatinib has been shown to decrease plexiform neurofibroma size.
Monitoring for any neurologic changes and referral to a neurologist is paramount. These changes can be due to tumor development. Consistent ophthalmologic evaluation is recommended for observation of the development of optic gliomas. Chemotherapy is the treatment of choice for optic gliomas.
Monitoring children for difficulty learning and behavioral issues is important. Counseling can be beneficial for patients to provide support regarding the disease's autosomal dominant inheritance pattern.
Neurofibromatosis Type 2
Neurofibromatosis type 2 patients require assessment of their hearing. Ophthalmology evaluation, MRI, audiology, and brainstem evoked potentials are important in managing these patients. Surgery is still the first line treatment for symptomatic tumors, but there is a 44% recurrence rate. Radiation can be used, but there is increased the risk of malignant transformation. Bevacizumab, a VEGF inhibitor, is a monoclonal antibody and can be used to treat neurofibromatosis type 2 patients medically. It decreased tumor size in 53% of cases and improved hearing in 57%. Patients with suspected neurofibromatosis type 2 should have an MRI of the head and spine done. Getting thin cuts through the internal auditory canals is important. Treatment is done if the tumor is compressing on the brainstem or preventing hearing loss. 
The management of neurofibromatosis is best done with an interprofessional team including dermatologists, neurologists, pediatricians, and genetic counselors. The key is to monitor the patient for CNS tumors, which if detected late have a poor prognosis. Genetic counseling should be available to patients with an affected child. The dermatologist, ophthalmologist, neurosurgeon, neurologist, and general surgeon should regularly follow up with these patients to ensure that no mass lesions are developing in the body.
|||Neurofibromatosis type 1., Boyd KP,Korf BR,Theos A,, Journal of the American Academy of Dermatology, 2009 Jul [PubMed PMID: 19539839]|
|||Neurofibromatosis type I (von Recklinghausen's disease): A family case report and literature review., Ghalayani P,Saberi Z,Sardari F,, Dental research journal, 2012 Jul [PubMed PMID: 23162593]|
|||Neurofibromatosis type 2., Asthagiri AR,Parry DM,Butman JA,Kim HJ,Tsilou ET,Zhuang Z,Lonser RR,, Lancet (London, England), 2009 Jun 6 [PubMed PMID: 19476995]|
|||The pathoetiology of neurofibromatosis 1., Jouhilahti EM,Peltonen S,Heape AM,Peltonen J,, The American journal of pathology, 2011 May [PubMed PMID: 21457932]|
|||Neurofibromatosis type 2 (NF2): a clinical and molecular review., Evans DG,, Orphanet journal of rare diseases, 2009 Jun 19 [PubMed PMID: 19545378]|
|||Neurofibromatosis type 2., Slattery WH,, Otolaryngologic clinics of North America, 2015 Jun [PubMed PMID: 26043141]|
|||Neurofibromatosis: A Review of NF1, NF2, and Schwannomatosis., Kresak JL,Walsh M,, Journal of pediatric genetics, 2016 Jun [PubMed PMID: 27617150]|
|||The development of cutaneous neurofibromas., Jouhilahti EM,Peltonen S,Callens T,Jokinen E,Heape AM,Messiaen L,Peltonen J,, The American journal of pathology, 2011 Feb [PubMed PMID: 21281783]|
|||Neurocutaneous Syndromes and Brain Tumors., Ullrich NJ,, Journal of child neurology, 2016 Oct [PubMed PMID: 26459515]|
|||Medical treatment in neurofibromatosis type 2. Review of the literature and presentation of clinical reports., Goutagny S,Kalamarides M,, Neuro-Chirurgie, 2017 Feb 2 [PubMed PMID: 28162254]|
|||Guidelines for the diagnosis and management of individuals with neurofibromatosis 1., Ferner RE,Huson SM,Thomas N,Moss C,Willshaw H,Evans DG,Upadhyaya M,Towers R,Gleeson M,Steiger C,Kirby A,, Journal of medical genetics, 2007 Feb [PubMed PMID: 17105749]|
|||Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial., Robertson KA,Nalepa G,Yang FC,Bowers DC,Ho CY,Hutchins GD,Croop JM,Vik TA,Denne SC,Parada LF,Hingtgen CM,Walsh LE,Yu M,Pradhan KR,Edwards-Brown MK,Cohen MD,Fletcher JW,Travers JB,Staser KW,Lee MW,Sherman MR,Davis CJ,Miller LC,Ingram DA,Clapp DW,, The Lancet. Oncology, 2012 Dec [PubMed PMID: 23099009]|
|||Neurofibromatosis type 1: a multidisciplinary approach to care., Hirbe AC,Gutmann DH,, The Lancet. Neurology, 2014 Aug [PubMed PMID: 25030515]|